World Library  
Flag as Inappropriate
Email this Article


Article Id: WHEBN0018509947
Reproduction Date:

Title: Eliprodil  
Author: World Heritage Encyclopedia
Language: English
Subject: NMDA receptor antagonist, NMDA receptor antagonists, Glycine, MMPIP, LY-307,452
Publisher: World Heritage Encyclopedia


Systematic (IUPAC) name
Clinical data
Legal status
CAS number  N
ATC code None
ChemSpider  YesY
Synonyms Eliprodil
Chemical data
Formula C20H23ClFNO 
Mol. mass 347.854 g/mol

Eliprodil (SL-82.0715) is a drug which acts as an NMDA antagonist, binding to the polyamine modulatory site.[1] It has neuroprotective and anticonvulsant effects in animal studies,[2] but does not support self-administration or substitute for phencyclidine,[3] and does not produce sedation or amnesia.[4] It was researched for the treatment of stroke[5] and epilepsy[6] but human trials failed to show clear beneficial effects.[7]


  1. ^ Dereń-Wesołek, A; Maj, J (1993). "Central effects of SL 82.0715, an antagonist of polyamine site of the NMDA receptor complex". Polish journal of pharmacology 45 (5–6): 467–80.  
  2. ^ Toulmond, S; Serrano, A; Benavides, J; Scatton, B (1993). "Prevention by eliprodil (SL 82.0715) of traumatic brain damage in the rat. Existence of a large (18 h) therapeutic window". Brain Research 620 (1): 32–41.  
  3. ^ Balster, RL; Nicholson, KL; Sanger, DJ (1994). "Evaluation of the reinforcing effects of eliprodil in rhesus monkeys and its discriminative stimulus effects in rats". Drug and alcohol dependence 35 (3): 211–6.  
  4. ^ Patat, A; Molinier, P; Hergueta, T; Brohier, S; Zieleniuk, I; Danjou, P; Warot, D; Puech, A (1994). "Lack of amnestic, psychotomimetic or impairing effect on psychomotor performance of eliprodil, a new NMDA antagonist". International clinical psychopharmacology 9 (3): 155–62.  
  5. ^ Reyes, M; Reyes, A; Opitz, T; Kapin, MA; Stanton, PK (1998). "Eliprodil, a non-competitive, NR2B-selective NMDA antagonist, protects pyramidal neurons in hippocampal slices from hypoxic/ischemic damage". Brain Research 782 (1–2): 212–8.  
  6. ^ Kohl, BK; Dannhardt, G (2001). "The NMDA receptor complex: a promising target for novel antiepileptic strategies". Current medicinal chemistry 8 (11): 1275–89.  
  7. ^ Ikonomidou, C; Turski, L (2002). "Why did NMDA receptor antagonists fail clinical trials for stroke and traumatic brain injury?". Lancet neurology 1 (6): 383–6.  

This article was sourced from Creative Commons Attribution-ShareAlike License; additional terms may apply. World Heritage Encyclopedia content is assembled from numerous content providers, Open Access Publishing, and in compliance with The Fair Access to Science and Technology Research Act (FASTR), Wikimedia Foundation, Inc., Public Library of Science, The Encyclopedia of Life, Open Book Publishers (OBP), PubMed, U.S. National Library of Medicine, National Center for Biotechnology Information, U.S. National Library of Medicine, National Institutes of Health (NIH), U.S. Department of Health & Human Services, and, which sources content from all federal, state, local, tribal, and territorial government publication portals (.gov, .mil, .edu). Funding for and content contributors is made possible from the U.S. Congress, E-Government Act of 2002.
Crowd sourced content that is contributed to World Heritage Encyclopedia is peer reviewed and edited by our editorial staff to ensure quality scholarly research articles.
By using this site, you agree to the Terms of Use and Privacy Policy. World Heritage Encyclopedia™ is a registered trademark of the World Public Library Association, a non-profit organization.

Copyright © World Library Foundation. All rights reserved. eBooks from World eBook Library are sponsored by the World Library Foundation,
a 501c(4) Member's Support Non-Profit Organization, and is NOT affiliated with any governmental agency or department.